Core Insights - Streamline Health Solutions, Inc. reported a net loss of 2.5millioninQ3fiscal2024,asignificantimprovementfromanetlossof11.9 million in Q3 fiscal 2023 [1][5] - The company reiterated its expectation for a 15.5millionimplementedSaaSARRadjustedEBITDAbreakevenrunrateandhasacceleratedthisexpectationtothefirsthalfoffiscal2025[1][10]FinancialPerformance−TotalrevenueforQ3fiscal2024was4.4 million, down from 6.1millioninQ3fiscal2023.FortheninemonthsendedOctober31,2024,revenuetotaled13.2 million compared to 17.2millioninthesameperiodoffiscal2023[3][21]−SaaSrevenueforQ3fiscal2024was2.9 million, representing 66% of total revenue, compared to 3.9million(648.7 million (66% of total revenue) compared to 10.6million(628.0 million, down from 17.3 million in the same period of fiscal 2023. This improvement was attributed to lower total revenues and higher interest expenses, offset by reductions in cost of sales, SG&A, and R&D expenses totaling 1.9 million and 5.3million,respectively[5][7]−AdjustedEBITDAforQ3fiscal2024wasalossof0.3 million, compared to a gain of 0.4millioninQ3fiscal2023.FortheninemonthsendedOctober31,2024,adjustedEBITDAwasalossof1.3 million, an improvement from a loss of 1.8millioninthesameperiodoffiscal2023[7][10]CashPosition−AsofOctober31,2024,cashandcashequivalentswere0.8 million, down from 3.2millionasofJanuary31,2024.ThecompanyhadnooutstandingbalanceonitsrevolvingcreditfacilityasofOctober31,2024,comparedto1.5 million as of January 31, 2024 [6][21] - The company received a 1.0milliondrawfromitsrevolvinglineofcreditonNovember20,2024[6]StrategicOutlook−Thecompany’stotalBookedSaaSAnnualContractValue(ACV)was14.1 million as of October 31, 2024, down from 15.0millionasofJanuary31,2024.However,12.0 million of the Booked SaaS ACV was implemented as of October 31, 2024, compared to $11.1 million as of January 31, 2024 [8][10] - Management expressed optimism about expanding client relationships and improving financial performance, leading to an accelerated timeline for achieving adjusted EBITDA breakeven [11]